{"id":1010187,"date":"2026-10-14T11:34:47","date_gmt":"2026-10-14T15:34:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/"},"modified":"2026-10-14T11:34:47","modified_gmt":"2026-10-14T15:34:47","slug":"editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/","title":{"rendered":"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Oct.  14, 2026  (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33<sup>rd<\/sup> Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>European Society of Gene and Cell Therapy (ESGCT) Congress<\/strong><br \/>\n          <br \/>\n          <strong>Title:<\/strong> Novel targeted LNP delivery achieved <em>in vivo<\/em> CAR-T cell generation resulting in therapeutically relevant B-cell depletion<br \/><strong>Session Date and Time: <\/strong>Wednesday, October 28, 2026, 1:30 &#8211; 3:30 p.m. CET<br \/><strong>Session Title:<\/strong> Poster Session 1<br \/><strong>Presenter: <\/strong>Harry An, Director, Process Development, Editas Medicine <br \/><strong>Final Abstract Number:<\/strong> P0361<\/p>\n<p><strong>Title: <\/strong>Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeutics<br \/><strong>Session Date and Time:<\/strong> Wednesday, October 28, 2026, 1:30 &#8211; 3:30 p.m. CET<br \/><strong>Session Title: <\/strong>Poster Session 1<br \/><strong>Presenter: <\/strong>Harry An, Director, Process Development, Editas Medicine<br \/><strong>Final Abstract Number:<\/strong> P0781<\/li>\n<\/ul>\n<p>Abstracts can be accessed on the conference website as they become available, and\u00a0presentations will also be posted to the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fMtAlRg1Flt6AhTsXLs1LCiJL9dZZL8golbhlXyXrjmSHXqJkfqwIvFJsE22KNfKg8FVLvdROEQ7VPEdC5niZTvM1xlgblrXJlb_wdZGyfDpXqBgt_mTFJ_xclIERMqCA_pBX7rno1rOufdI_WwKmxXZMVPicQdu-mR9kM3ki2Q1i6e9s5HibgIjClgnU9LNHR9ACh1JgKNYeg8eiuG4sbNJifjXl6nUTHxfcj9TzAr28q2I-HNRxwbHUFvu8Fi-c62J8E5AQiLYsTASwT4ogblmiLBn4lm8CEn2fzcRWuD-TPgjFMAbpO8kAvmr1tI3PEXr1otssf6VJDCEvkvsqg==\" rel=\"nofollow\" target=\"_blank\">Posters &amp; Presentations<\/a>\u201d section of the Company\u2019s website during the conferences.<\/p>\n<p>In addition, management will participate in the following upcoming investor conference in November:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Guggenheim 3<\/strong><br \/>\n          <sup><br \/>\n            <strong>rd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong>\u00a0Annual Healthcare Innovation Conference\u00a0<\/strong><br \/>\n          <br \/>Format:\u00a0Fireside Chat<br \/>Date and Time: November 10, 2026, 2:30 p.m. ET<br \/>Location: Boston, Massachusetts<\/li>\n<\/ul>\n<p>To access the live webcast of Editas Medicine\u2019s Fireside Chat, please visit the \u201cInvestors\u201d section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1hB4-S2WAZ9A_f1zhD2rEK3Jm8l2xvSwqX8Retumuzvn7Lm-e1e096sNBXC_mE-tUdKsqntRdJZUUwUFwiryXD8IU0AVDjJCgiDxL2VzswptxjdsJEzVnCpXyIT4YbpytpXgsgtX_S9h_-_oJ84x6IhWptxrpiesKDwE_ZDFHYZAxGvY0lh_um0jBpUeGYYUeAQpdjp0Y8sONobB2KqGpltZlhvegiyBuxQTfDAy1p40oCM-gVcoSRKFOOFpJf2ZoCwroFIUh2Fdm5Vb-PUeGQ==\" rel=\"nofollow\" target=\"_blank\">www.editasmedicine.com<\/a>. An archived replay will be available for approximately 30 days following the event.<\/p>\n<p>\n        <strong>About Editas Medicine<\/strong><br \/>\n        <br \/>As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative\u00a0<em>in vivo<\/em>\u00a0medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision\u00a0<em>in vivo<\/em>\u00a0gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute\u2019s Cas12a patent estate and Broad Institute and Harvard University\u2019s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1hB4-S2WAZ9A_f1zhD2rEK3Jm8l2xvSwqX8Retumuzsx0BYi9xy1FPKJRHpsTILKisXr2TfQ_UHre90Tx3iI1btpEEc5ytu-ZqtXIf7bhA8=\" rel=\"nofollow\" target=\"_blank\">www.editasmedicine.com<\/a>.<\/p>\n<p>\n        <strong>Investor and Media Contacts:<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B7OH9s_C4RgiYmmH3KSxNyocGTSWha-kpmWh4UE6yAVfKtDB_4zAi63u7IfNmTE0TzLqjOohOS3s0Llcw13ESZ-gA_H_wBLgnmdWAz9Lysc=\" rel=\"nofollow\" target=\"_blank\">ir@editasmed.com<\/a><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zDip_vYtTZgQ7mrMC5wuaA5sLcFAZKT_AD4ehLaO6ywrk3A0UeeXade6Cm8ArIQySTn3F5OvpWSBUI9CRyxGuQ7MAy2gP3npE_tuumslvZY=\" rel=\"nofollow\" target=\"_blank\">media@editasmed.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2ZkZjg2NjYtZmNkNS00ZjY5LWJlOGYtZTQyNWI0ZGYxNmU3LTEwMzc1OTktMjAyNi0xMC0xNC1lbg==\/tiny\/Editas-Medicine-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany. European Society of Gene and Cell Therapy (ESGCT) Congress Title: Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletionSession Date and Time: Wednesday, October 28, 2026, 1:30 &#8211; 3:30 p.m. CETSession Title: Poster Session 1Presenter: Harry An, Director, Process Development, Editas Medicine Final Abstract Number: P0361 Title: Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeuticsSession Date and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1010187","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany. European Society of Gene and Cell Therapy (ESGCT) Congress Title: Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletionSession Date and Time: Wednesday, October 28, 2026, 1:30 &#8211; 3:30 p.m. CETSession Title: Poster Session 1Presenter: Harry An, Director, Process Development, Editas Medicine Final Abstract Number: P0361 Title: Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeuticsSession Date and &hellip; Continue reading &quot;Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-14T15:34:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference\",\"datePublished\":\"2026-10-14T15:34:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/\"},\"wordCount\":376,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/\",\"name\":\"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=\",\"datePublished\":\"2026-10-14T15:34:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany. European Society of Gene and Cell Therapy (ESGCT) Congress Title: Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletionSession Date and Time: Wednesday, October 28, 2026, 1:30 &#8211; 3:30 p.m. CETSession Title: Poster Session 1Presenter: Harry An, Director, Process Development, Editas Medicine Final Abstract Number: P0361 Title: Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeuticsSession Date and &hellip; Continue reading \"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-14T15:34:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference","datePublished":"2026-10-14T15:34:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/"},"wordCount":376,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/","name":"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=","datePublished":"2026-10-14T15:34:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NDk3NSM3ODkzNzE1IzIwMjYwMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1010187"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010187\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1010187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1010187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1010187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}